60 completed, 36 unknown, 21 terminated, 13 recruiting. 70 Phase 2, 33 Phase 1, 16 Phase 3, 11 Not applicable, 8 Phase 4.
Follow Non-Small-Cell Lung Cancer: new trials by email Literature Review of Non-Small-Cell Lung Cancer trials Research Report on Non-Small-Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression Vebreltinib, Furmonertinib 80mg - Non-Small-Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital of Nanchang University | 45 | 2026-07-03 | 2026-06-18 |
| Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II Trial Paclitaxel Oral Solution - Non-Small-Cell Lung Cancer, Neoadjuvant Therapy | Not applicable | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 75 | 2026-06-08 | 2026-05-20 |
| Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations PLB1004 - Non-Small-Cell Lung Cancer | Phase 2 | Recruiting | Avistone Biotechnology Co., Ltd. | 40 | 2026-03-11 | 2026-03-20 |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations Firmonertinib, EGFR-TKI inhibitor based on investigator's choice - Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer | Phase 3 | Recruiting | ArriVent BioPharma, Inc. | 480 | 2025-12-17 | 2026-10-14 |
| A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors ASP5834, panitumumab - Solid Tumor, Non-Small-Cell Lung Cancer | Phase 1 | Recruiting | Astellas Pharma Inc | 404 | 2025-07-25 | 2026-10-29 |
| Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure Vebreltinib, PLB1004, Pemetrexed plus Carboplatin or Cisplatin - Non-Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | Avistone Biotechnology Co., Ltd. | 278 | 2025-05-15 | 2025-05-21 |
| Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC Vebreltinib, Osimertinib - Non-Small-Cell Lung Cancer | Phase 2 | Active not recruiting | National Cancer Center, China | 30 | 2024-10-14 | 2025-02-14 |
| Efficacy and Safety of Combination Therapy of Sintilimab and Chemotherapy With Cryoablation in NSCLC Cryoablation - Non-Small-Cell Lung Cancer | Phase 4 | Not yet recruiting | Shanghai Chest Hospital | 20 | 2024-10-01 | 2024-08-30 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| Real-World Assessment of Therapeutic Strategies and Survival Outcomes Following First-Line Tislelizumab Therapy in Advanced Non-Small Cell Lung Cancer Non-Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer Stage IV | Enrolling by invitation | Shanghai Chest Hospital | 500 | 2024-08-16 | 2025-05-08 | |
| Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. Vebreltinib, Osimertinib, PLB1004 - Non-Small-Cell Lung Cancer | Phase 2 | Recruiting | Avistone Biotechnology Co., Ltd. | 120 | 2024-08-07 | 2025-05-21 |
| SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer Anlotinib hydrochloride - Non-Small-Cell Lung Cancer, Brain Metastases | Not applicable | Recruiting | The First People's Hospital of Lianyungang | 46 | 2024-07-01 | 2024-06-26 |
| A Study of SBRT Combined With Puterizumab in Intrapulmonary Metastasis From NSCLC Stereotactic Body Radiation Therapy，SBRT, Puterizumab - Non-Small-Cell Lung Cancer | Phase 2 | Not yet recruiting | Sir Run Run Shaw Hospital | 37 | 2024-06-01 | 2024-05-30 |
| Nutritional Assessment of Patients With Non-small Cell Lung Cancer Treated With Osimertinib Unic group - Non-small-cell Lung Cancer, Sarcopenia | Completed | Fundacin Biomedica Galicia Sur | 25 | 2024-03-20 | 2026-04-30 | |
| Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations Non-small-cell Lung Cancer | Active not recruiting | AstraZeneca | 1500 | 2024-03-20 | 2026-06-15 | |
| A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors PF-07820435, Sasanlimab - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 9 | 2024-02-08 | 2025-09-17 |
| Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) Golidocitinib, Sintilimab, platinum doublet chemotherapy - Non-Small-Cell Lung Cancer | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 69 | 2024-01-01 | 2024-01-10 |
| Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. PLB1004, Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab - Non-Small-Cell Lung Cancer | Phase 3 | Enrolling by invitation | Avistone Biotechnology Co., Ltd. | 327 | 2023-12-01 | 2026-04-23 |
| Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study HL-085+Vemurafenib - Non-small-cell Lung Cancer | Phase 2 | Unknown | Shanghai Kechow Pharma, Inc. | 75 | 2023-09-24 | 2023-06-12 |
| Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI Vebreltinib, PLB1004 - Non-Small-Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | Avistone Biotechnology Co., Ltd. | 156 | 2023-06-13 | 2025-05-21 |
Showing 20 of 148. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (148) · Lung Neoplasms (25) · Neoplasms (16) · Carcinoma (9) · Colorectal Neoplasms (8) · Melanoma (8) · Carcinoma, Renal Cell (7) · Ovarian Neoplasms (6) · Adenocarcinoma (5) · Neoplasm Metastasis (5) · Breast Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (4) · Adenocarcinoma of Lung (3) · Carcinoma, Squamous Cell (3) · Carcinoma, Transitional Cell (3)
Carcinoma, Bronchogenic (148) · Neoplasms by Site (148) · Bronchial Neoplasms (147) · Respiratory Tract Neoplasms (147) · Lung Diseases (146) · Respiratory Tract Diseases (146) · Thoracic Neoplasms (145) · Neoplasms (132) · Lung Neoplasms (123) · Neoplasms by Histologic Type (30) · Neoplasms, Glandular and Epithelial (28) · Carcinoma (15) · Skin Diseases (13) · Skin and Connective Tissue Diseases (13) · Adenocarcinoma (12)
Pemetrexed (21) · Carboplatin (16) · Cisplatin (16) · Docetaxel (11) · Erlotinib Hydrochloride (9) · Paclitaxel (8) · Gefitinib (7) · Gemcitabine (6) · aflutinib (5) · Bevacizumab (4) · icotinib (4) · ARQ 197 (3) · Cetuximab (3) · Radiotherapy (3) · SHR-1701 (3)
Eli Lilly and Company (8) · Pfizer (8) · Avistone Biotechnology Co., Ltd. (6) · Novartis Pharmaceuticals (6) · Peking University People's Hospital (6) · AstraZeneca (5) · Hellenic Oncology Research Group (5) · Shanghai Chest Hospital (5) · Jiangsu HengRui Medicine Co., Ltd. (4) · Betta Pharmaceuticals Co., Ltd. (3) · GlaxoSmithKline (3) · Guangdong Association of Clinical Trials (3) · Kyowa Kirin Co., Ltd. (3) · Taipei Veterans General Hospital, Taiwan (3) · Bristol-Myers Squibb (2)
China (57) · United States (41) · Japan (15) · Spain (14) · Taiwan (14) · Canada (12) · Greece (11) · Italy (10) · France (9) · United Kingdom (9) · Germany (8) · South Korea (7) · Netherlands (5) · Poland (5) · Russia (5)
Jun Wang, M.D. (4) · Yuh-Min Chen, MD, PhD. (3) · Athanasios Karampeazis, MD (2) · Juan Li, MD (2) · Lampros Vamvakas, MD (2) · Manolis Kontopodis, MD (2) · Sofia Agelaki, MD (2) · Yilong Wu, MD (2) · Aiqin Gu, Master (1)
PMID 16012180, PMID 16807466, PMID 19487962, PMID 19692680, PMID 20516435, PMID 21108883, PMID 21300929, PMID 21617977, PMID 22326218, PMID 22461641, PMID 22730101, PMID 23332288, PMID 23350714, PMID 23860537, PMID 23890768, PMID 24668644, PMID 25028118, PMID 25378648, PMID 25747273, PMID 25783515, PMID 26153496, PMID 26228759, PMID 26703796, PMID 26871284, PMID 27153497, PMID 27236466, PMID 27264267, PMID 27607176, PMID 27659017, PMID 27683031, PMID 27690345, PMID 27710970, PMID 27729297, PMID 27843623, PMID 28215851, PMID 29247830, PMID 29437753, PMID 29959809, PMID 30773184, PMID 30785829, PMID 31200823, PMID 31439586, PMID 32134163, PMID 32170554, PMID 33331923, PMID 34156285, PMID 34339261, PMID 34339292, PMID 34473939, PMID 34530760
2023 (2), 2004 (1), 2018 (1), 2019 (1), 2025 (1), P01CA021239 (1), R01CA157409 (1)